

Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/131015/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Gadsbøll, Kasper, Petersen, Olav Bjørn, Gatinois, Vincent, Strange, Heather, Jacobsson, Bo, Wapner, Ronald, Robert Vermeesch, Joris, Vogel, Ida, Shand, Antonia, Nowakowska, Beata, Peterlin, Borut, Machtejeviene, Egle, Sethna, Farah, Stipoljev, Feodora, Szirko, Ferenc, Romana Grati, Francesca, Minarik, Gabriel, Duncombe, Greg, Helmer, Hanns, Hardardottir, Hildur, Lebedev, Igor, Dickinson, Jan, Melo, Joana B., Edwards, Lindsay, Hui, Lisa, Srebniak, Malgorzata I., de Alba, Marta Rodriguez, Vedmedovska, Natalija, Calda, Pavel, Celec, Petet, Muller, Peter, Patsalis, Philippos, Popp, Radu, Liehr, Thomas, Moe Eggebø, Torbjørn, Stefanovic, Vedran and Velissariou, Voula 2020. Current use of noninvasive prenatal testing in Europe, Australia and the USA: A graphical presentation. *Acta Obstetrica et Gynecologica Scandinavica* 99 (6) , pp. 722-730. 10.1111/aogs.13841 filefilefilefilefilefile

Publishers page: <http://dx.doi.org/10.1111/aogs.13841>
<<http://dx.doi.org/10.1111/aogs.13841>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies.

See

<http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Enter country/state name:

The form is filled out by:

Affiliation:

1. Access to NIPT - To what extent is NIPT used as a national prenatal offer/recommendation:

- 1 No national recommendation/offer including NIPT
- 2 cFTS with invasive testing or NIPT for high risk (after cFTS)
- 3 NIPT for all
- 4 NIPT on special indication (e.g. age > 35)

Comment:

2. NIPT most commonly covers/includes:

- 1. Chromosome 13, 18, 21
- 2. Chromosome 13, 18, 21, sex chromosome aneuploidy (SCA)
- 3. Chromosome 13, 18, 21, a few microdeletions (22q11 etc), ±Sex chromosome aneuploidy (SCA)
- 4. Chromosome 13, 18, 21, Whole Genome coverage (WGS)

Comment:

3. NIPT financial coverage in patients offered NIPT

- 1. Self-paid/pay out of pocket
- 2. Partially or fully reimbursed medicaid/health care system
- 3. Partially or fully reimbursed by health insurance

Comment:

4. Percentage of women receiving NIPT

- 1. <25%
- 2. 25-50%
- 3. 50-75%
- 4. >75%
- No data available, this is my best clinical guess

Comment: